Remdesivir Reduced Mortality in Immunocompromised Patients Hospitalized for COVID-19 Across Variant Waves: Findings From Routine Clinical Practice

• Published in: Clinical infectious diseases 2023-12, Vol.77 (12), p.1626-1634
• Main Authors: Mozaffari, Essy, Chandak, Aastha, Gottlieb, Robert L, Chima-Melton, Chidinma, Read, Stephanie H, Jiang, Heng, Chiang, Mel, Lee, EunYoung, Gupta, Rikisha, Berry, Mark, Kalil, Andre C
• Format: Article
• Language: English
• Subjects: Major
• ISSN: 1058-4838; 1537-6591; 1537-6591
• DOI: 10.1093/cid/ciad460

Abstract Background Immunocompromised patients are at high risk of severe coronavirus disease 2019 (COVID-19) and death, yet treatment strategies for immunocompromised patients hospitalized for COVID-19 reflect variations in clinical practice. In this comparative effectiveness study, we investigated the effect of remdesivir treatment on inpatient mortality among immunocompromised patients hospitalized for COVID-19 across all variants of concern (VOC) periods. Methods Data for immunocompromised patients hospitalized for COVID-19 between December 2020 and April 2022 were extracted from the US PINC AITM Healthcare Database. Patients who received remdesivir within 2 days of hospitalization were matched 1:1 using propensity score matching to patients who did not receive remdesivir. Additional matching criteria included admission month, age group, and hospital. Cox proportional hazards models were used to examine the effect of remdesivir on risk of 14- and 28-day mortality during VOC periods. Results A total of 19 184 remdesivir patients were matched to 11 213 non-remdesivir patients. Overall, 11.1% and 17.7% of remdesivir patients died within 14 and 28 days, respectively, compared with 15.4% and 22.4% of non-remdesivir patients. Remdesivir was associated with a reduction in mortality at 14 (hazard ratio [HR], 0.70; 95% confidence interval, .62–.78) and 28 days (HR, 0.75; 95% CI, .68–.83). The survival benefit remained significant during the pre-Delta, Delta, and Omicron periods. Conclusions Prompt initiation of remdesivir in immunocompromised patients hospitalized for COVID-19 is associated with significant survival benefit across all variant waves. These findings provide much-needed evidence relating to the effectiveness of a foundational treatment for hospitalized COVID-19 patients among a high-risk population. Immunocompromised patients are at high risk of mortality from coronavirus disease 2019 (COVID-19). Early initiation of remdesivir is associated with a significant reduction in 14- and 28-day mortality among immunocompromised patients hospitalized for COVID-19. Graphical Abstract Graphical Abstract This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/remdesivir-reduced-mortality-in-immunocompromised-patients-hospitalized-for-covid-19-across-variant-waves-findings-from-routine-clinical-practice